(Q37851221)

24 August 2017

1 reference

title

Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates (English)

1 reference

24 August 2017

1 reference

2

Michael Souvatzoglou

1 reference

24 August 2017

Bernd Joachim Krause

1

1 reference

24 August 2017

Uwe Treiber

series ordinal

3

1 reference

24 August 2017

publication date

8 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

31

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

427-435

1 reference

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical Prostatectomy

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

(11)C-acetate PET in the early evaluation of prostate cancer recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Positron tomographic assessment of androgen receptors in prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Experience with carbon-11 choline positron emission tomography in prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Detection of prostate cancer with 11C-methionine positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Choline phospholipid metabolism: a target in cancer cells?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Choline transporter as a novel target for molecular imaging of cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Effects of irradiation on the [Methyl-3H]choline uptake in the human prostate cancer cell lines LNCaP and PC3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Visualization of prostate cancer with 11C-choline positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Fluorocholine PET/CT in patients with prostate cancer: initial experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Management of recurrent disease after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

PET in oncology: will it replace the other modalities?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Monitoring predominantly cytostatic treatment response with 18F-FDG PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Systemic disseminated tuberculosis mimicking malignancy on F-18 FDG PET-CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.08.008

10.1016/J.UROLONC.2010.08.008

7 January 2021

Identifiers

DOI

1 reference

24 August 2017

1 reference